Company intelligence / Profile preview

CABA Capital

Philadelphia, Pennsylvania, United Statescabacapital.dk ↗

Ownership: Private
Development stage: Other

Overview

Early clinical results show favorable safety profile for rese-cel with most patients experiencing no or only mild cytokine release syndrome and no neurotoxicity. Data presented at ACR Convergence November 2024 showed drug-free responses in initial patients dosed across SLE and other autoimmune diseases. The company is expanding into additional indications such as multiple sclerosis with Fast Track Designation granted by FDA.

Therapeutic areas: DermatologyRheumatologyImmunologyNeurology
Modalities: CAR-T cell therapyCell therapyCAAR-T cell therapy
Industry: Biotech

Partnerships

University of PennsylvaniaChildren’s Hospital of PhiladelphiaNanjing IASO Biotherapeutics Co., LtdOxford BiomedicaWuXi Advanced Therapies Inc.

Beyond the preview

Go deeper on CABA Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CABA Capital.

Explore the full profile